| Autor: |
Harald Petry, Hu Sheng Qian, Maxine Bauzon, Peiyin Wang, Jude Samulski, Linda Cashion, Cynthia Gross, Terry Hermiston, Ann Orme, Perry Liu, Gabor M. Rubanyi, Paul Szymanski, Alan R. Brooks, Oliver Ast, Richard N. Harkins |
| Rok vydání: |
2005 |
| Předmět: |
|
| Zdroj: |
Molecular Therapy. 11:S370 |
| ISSN: |
1525-0016 |
| Popis: |
Interferon beta (IFN-) has been shown to be an effective drug for patients with multiple sclerosis (MS). However dose-dependent side effects from administration of IFN- protein have limited its therapeutic efficacy and clinical utility. IFN- gene therapy offers an alternative approach to overcome these obstacles, and it would be advantageous over bolus delivery of protein. A critical issue in developing such a new approach is in vivo detection of biologically active IFN- in pre-clinical animal models. Several biomarkers have been established in humans undergoing IFN- therapy, including MxA (myxovirus resistant protein) an antiviral protein induced by IFN-. The goal of the present study was to establish and validate a quantitative PCR-based assay to measure RNA expression of Mx1, the murine homologue of human MxA, in peripheral blood mononuclear cells (PBMC) of mice following IFN- protein administration or gene-based delivery. In parallel it was investigated whether IP10, which was recently reported to be up-regulated following IFN- treatment in MS patients, could also be used as biomarker in mice. IP-10 has the advantage that it can be assayed directly by ELISA in plasma samples. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
